180 related articles for article (PubMed ID: 24018401)
1. Chronic kidney disease induced dysfunction of high density lipoprotein.
Yamamoto S; Kon V
Clin Exp Nephrol; 2014 Apr; 18(2):251-4. PubMed ID: 24018401
[TBL] [Abstract][Full Text] [Related]
2. Importance of high-density lipoprotein quality: evidence from chronic kidney disease.
Kon V; Ikizler TA; Fazio S
Curr Opin Nephrol Hypertens; 2013 May; 22(3):259-65. PubMed ID: 23470818
[TBL] [Abstract][Full Text] [Related]
3. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
Kon V; Yang H; Fazio S
Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
[TBL] [Abstract][Full Text] [Related]
4. The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.
Rysz J; Gluba-Brzózka A; Rysz-Górzyńska M; Franczyk B
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963445
[TBL] [Abstract][Full Text] [Related]
5. Dysfunctional high-density lipoproteins in children with chronic kidney disease.
Kaseda R; Jabs K; Hunley TE; Jones D; Bian A; Allen RM; Vickers KC; Yancey PG; Linton MF; Fazio S; Kon V
Metabolism; 2015 Feb; 64(2):263-73. PubMed ID: 25467845
[TBL] [Abstract][Full Text] [Related]
6. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease.
Rysz-Gorzynska M; Gluba-Brzozka A; Banach M
Curr Vasc Pharmacol; 2017; 15(2):144-151. PubMed ID: 27697068
[TBL] [Abstract][Full Text] [Related]
7. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.
Zewinger S; Kleber ME; Rohrer L; Lehmann M; Triem S; Jennings RT; Petrakis I; Dressel A; Lepper PM; Scharnagl H; Ritsch A; Thorand B; Heier M; Meisinger C; de Las Heras Gala T; Koenig W; Wagenpfeil S; Schwedhelm E; Böger RH; Laufs U; von Eckardstein A; Landmesser U; Lüscher TF; Fliser D; März W; Meinitzer A; Speer T
Eur Heart J; 2017 May; 38(20):1597-1607. PubMed ID: 28379378
[TBL] [Abstract][Full Text] [Related]
8. Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.
Marsche G; Heine GH; Stadler JT; Holzer M
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32967334
[TBL] [Abstract][Full Text] [Related]
9. High-Density Lipoproteins and the Kidney.
Strazzella A; Ossoli A; Calabresi L
Cells; 2021 Mar; 10(4):. PubMed ID: 33807271
[TBL] [Abstract][Full Text] [Related]
10. Lipid disorders and their relevance to outcomes in chronic kidney disease.
Vaziri ND; Norris K
Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
[TBL] [Abstract][Full Text] [Related]
11. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.
Noels H; Lehrke M; Vanholder R; Jankowski J
Nat Rev Nephrol; 2021 Aug; 17(8):528-542. PubMed ID: 33972752
[TBL] [Abstract][Full Text] [Related]
12. Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: A nationwide population-based study.
Lee Y; Park S; Lee S; Kim Y; Kang MW; Cho S; Park S; Han K; Kim YC; Han SS; Lee H; Lee JP; Joo KW; Lim CS; Kim YS; Kim DK
PLoS One; 2020; 15(4):e0231328. PubMed ID: 32271842
[TBL] [Abstract][Full Text] [Related]
13. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
14. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.
Heine GH; Rogacev KS; Weingärtner O; Marsche G
Semin Dial; 2017 Sep; 30(5):390-394. PubMed ID: 28628255
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Hyperlipidemia Changes With Level of Kidney Function-Rationale.
Ananthakrishnan S; Kaysen GA
Adv Chronic Kidney Dis; 2016 Jul; 23(4):247-54. PubMed ID: 27324678
[TBL] [Abstract][Full Text] [Related]
16. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
17. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.
Vaziri ND
Clin Exp Nephrol; 2014 Apr; 18(2):265-8. PubMed ID: 23974528
[TBL] [Abstract][Full Text] [Related]
18. Relationship between High-density Lipoprotein Cholesterol and Insulin Resistance in Non-diabetic Chronic Kidney Disease Patients.
El-Hendy YA; Ismail MI; Borai MM; Abdelhamid WAR
Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):323-330. PubMed ID: 38345587
[TBL] [Abstract][Full Text] [Related]
19. Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.
Maeba R; Kojima KI; Nagura M; Komori A; Nishimukai M; Okazaki T; Uchida S
Atherosclerosis; 2018 Mar; 270():102-109. PubMed ID: 29407877
[TBL] [Abstract][Full Text] [Related]
20. Lipoproteins in chronic kidney disease: from bench to bedside.
Speer T; Ridker PM; von Eckardstein A; Schunk SJ; Fliser D
Eur Heart J; 2021 Jun; 42(22):2170-2185. PubMed ID: 33393990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
